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Neurobiology of Disease
Transient P2X7 Receptor Antagonism Produces Lasting
Reductions in Spontaneous Seizures and Gliosis in
Experimental Temporal Lobe Epilepsy
XAlba Jimenez-Pacheco,1 XMiguel Diaz-Hernandez,3 XMarina Arribas-Bla´zquez,4,5 Amaya Sanz-Rodriguez,1
Luis A. Olivos-Ore´,4,5 Antonio R. Artalejo,4,5 Mariana Alves,1 Michael Letavic,6 M. Teresa Miras-Portugal,3,5
XRonanM. Conroy,2 Norman Delanty,7 Michael A. Farrell,7 Donncha F. O’Brien,7 Anindya Bhattacharya,6
Tobias Engel,1* and David C. Henshall1*
1Department of Physiology and Medical Physics, and 2Division of Population Health Sciences, Royal College of Surgeons in Ireland, Dublin 2, Ireland,
Departments of 3Biochemistry and 4Toxicology and Pharmacology, Faculty of Veterinary Medicine, and 5Instituto de Investigación en Neuroquímica,
Universidad Complutense de Madrid, Madrid 28040, Spain, 6Janssen Research & Development, LLC, Neuroscience, La Jolla, California 92121, and
7Beaumont Hospital, Beaumont, Dublin 9, Ireland
Neuroinflammation is thought to contribute to the pathogenesis andmaintenance of temporal lobe epilepsy, but the underlying cell and
molecularmechanisms are not fully understood. The P2X7 receptor is an ionotropic receptor predominantly expressed on the surface of
microglia, althoughneuronal expression has also been reported. The receptor is activated by the release ofATP from intracellular sources that
occurs during neurodegeneration, leading to microglial activation and inflammasome-mediated interleukin 1 release that contributes to
neuroinflammation.Usingareportermouseinwhichgreenfluorescentproteinis inducedinresponsetothetranscriptionofP2rx7,weshowthat
expressionof the receptor is selectively increased inCA1pyramidal anddentate granule neurons, aswell as inmicroglia inmice that developed
epilepsy after intra-amygdala kainic acid-induced status epilepticus. P2X7 receptor levels were increased in hippocampal subfields in themice
andinresectedhippocampusfrompatientswithpharmacoresistant temporal lobeepilepsy.Cells transcribingP2rx7 inhippocampalslices from
epileptic mice displayed enhanced agonist-evoked P2X7 receptor currents, and synaptosomes from these animals showed increased P2X7
receptor levels and altered calcium responses. A 5 d treatment of epileptic mice with systemic injections of the centrally available, potent, and
specific P2X7 receptor antagonist JNJ-47965567 (30mg/kg) significantly reduced spontaneous seizuresduring continuous video-EEGmonitor-
ing thatpersistedbeyond the timeofdrugpresence in thebrain.Hippocampal sections fromJNJ-47965567-treatedanimalsobtained5dafter
treatment ceased displayed strongly reduced microgliosis and astrogliosis. The present study suggests that targeting the P2X7 receptor has
anticonvulsant and possibly disease-modifying effects in experimental epilepsy.
Key words: anticonvulsant; hippocampal sclerosis; inflammatory cytokine; microglia; purinergic receptor; status epilepticus
Introduction
Temporal lobe epilepsy (TLE) is a common and often refractory
brain disease characterized by recurrent seizures originating from
or involving structures such as the hippocampus (Fisher et al.,
2014; Moshe´ et al., 2015). The first-line treatment for TLE pa-
tients is with antiepileptic drugs (AEDs). These work through
mechanisms including blocking sodium and calcium channels
Received Nov. 6, 2015; revised March 24, 2016; accepted March 26, 2016.
Author contributions: A.J.-P., L.A.O.-O., A.R.A., M.T.M.-P., N.D., M.F., T.E., and D.C.H. designed research; A.J.-P.,
M.D.-H., M.A.-B., L.A.O.-O., A.R.A., M.A., and T.E. performed research; A.S.-R., M.L., N.D., M.F., D.O., and A.B. con-
tributed unpublished reagents/analytic tools; A.J.-P., M.D.-H., A.S.-R., R.C., A.B., and T.E. analyzed data; D.C.H.
wrote the paper.
Significance Statement
Temporal lobe epilepsy is themost common and drug-resistant form of epilepsy in adults. Neuroinflammation is implicated as a
pathomechanism, but the upstream mechanisms driving gliosis and how important this is for seizures remain unclear. In our
study, we show that the ATP-gated P2X7 receptor is upregulated in experimental epilepsy and resected hippocampus from
epilepsy patients. Targeting the receptor with a new centrally available antagonist, JNJ-47965567, suppressed epileptic seizures
well beyond the time of treatment and reduced underlying gliosis in the hippocampus. The findings suggest a potential disease-
modifying treatment for epilepsy based on targeting the P2X7 receptor.
5920 • The Journal of Neuroscience, June 1, 2016 • 36(22):5920–5932
and promoting GABA function (Bialer and White, 2010). Cur-
rent AEDs are ineffective, however, in30% of epilepsy patients
and do not alter the underlying pathophysiology. The identifica-
tion of treatments for TLE with novel mechanisms of action and,
ideally, disease-modifying effects would be transformational (Bi-
aler and White, 2010; Pitka¨nen and Lukasiuk, 2011).
There is emerging interest in targeting gliosis and neuroin-
flammation as an approach to pharmacoresistant epilepsy and
antiepileptogenesis (Bialer andWhite, 2010; Vezzani et al., 2011;
Devinsky et al., 2013; Marchi et al., 2014). Astrocyte expansion
and proliferation interferes with the normal reuptake of neu-
rotransmitters and glia–neuron metabolic coupling and reduces
inhibitory adenosinergic tone (Haydon and Carmignoto, 2006;
Li et al., 2007; Devinsky et al., 2013). Microglia activation and
proliferation can also promote hyperexcitability through neuro-
toxic and neuroinflammatory mechanisms (Allan et al., 2005;
Block et al., 2007; Devinsky et al., 2013; Salter and Beggs, 2014).
In particular, activated microglia release the cytokine inter-
leukin-1 (IL-1), resulting in potentiated glutamatergic and
reduced GABAergic signaling, as well as astrogliosis (Allan et al.,
2005; Vezzani et al., 2011). Gene networks associated with IL-1
are a key molecular signature in resected hippocampi from TLE
patients (Johnson et al., 2015), and targeting IL-1 has been re-
ported to reduce seizures in animal models (Vezzani et al., 2010;
Maroso et al., 2011).
Evidence is emerging that ATP is a key upstream trigger of
neuroinflammation (Eltzschig et al., 2013; Idzko et al., 2014).
ATP is released in high quantities after damage to the CNS, where
it acts on plasma membrane receptors (Wang et al., 2004; Ab-
bracchio et al., 2009; Idzko et al., 2014). The fast excitatory effects
of extracellular ATP are mediated by the P2X class ionotropic
receptors. The P2X7 receptor (P2X7R) has the lowest affinity for
ATP and, as such, is activated mainly under conditions of patho-
logic release of ATP (high M–low mM). The P2X7R gates depo-
larizing sodium and calcium entry, and triggers downstream
proinflammatory signaling cascades. This includes the activation
and proliferation of microglia and the formation of the inflam-
masome that releases IL-1 (Monif et al., 2009; Surprenant and
North, 2009).More controversially, the P2X7Rhas been reported
to be expressed, although at lower expression levels, by certain
neurons, where it modulates neurotransmitter release (Arm-
strong et al., 2002; Sperla´gh et al., 2002;Duan et al., 2003;Wang et
al., 2004; Fellin et al., 2006; Jabs et al., 2007). Although the P2X7R
has emerged as an important target in neurological disorders
(Sperla´gh and Illes, 2014), a role in epilepsy is unclear. The
P2X7R is overexpressed in epileptic rats (Vianna et al., 2002;
Rappold et al., 2006; Dona´ et al., 2009), and P2X7R levels are
elevated in resected neocortex from TLE patients (Jimenez-
Pacheco et al., 2013). Functional studies have been limited to the
analysis of P2X7R antagonists, including A-438079 and brilliant
blue G or genetic manipulation on acute chemoconvulsant re-
sponses, with mixed results (Kim and Kang, 2011; Engel et al.,
2012b; Jimenez-Pacheco et al., 2013; Mesuret et al., 2014; Soni et
al., 2015).
Here we investigated P2X7R expression and function in ex-
perimental and human TLE. Our hypothesis was that neurons as
well as microglia express P2X7R, and that targeting the receptor
would reduce hyperexcitability and gliosis in the epileptic brain.
We took advantage of a reportermouse to specifically identify the
cell types expressing the receptor and tested a new centrally avail-
able P2X7R antagonist for effects on spontaneous recurrent sei-
zures in mice.
Materials andMethods
Animal model of epilepsy. Animal experiments were performed in accor-
dance with the principles of a European Communities Council Directive
(86/609/EEC, 2010/63/EU), under licenses from the Department of
Health and Health Products Regulatory Authority (Ireland), and proce-
dures were approved by the Research Ethics Committee of the Royal
College of Surgeons in Ireland.Male adult C57BL/6mice (weight, 20–25
g; age, 6–9 weeks), were obtained from Harlan Laboratories and main-
tained in a vivarium with access to food and water ad libitum. P2X7R
reporter mice [Tg(P2rx7-EGFP)FY174Gsat/Mmcd, stock 011959-UCD]
were obtained from US National Institutes of Health Mutant Mouse
Regional Resource Centers (University of Rochester, Rochester, NY). To
generate these mice, an enhanced green fluorescent protein (EGFP) re-
porter gene, followed by a polyadenylation sequence, was inserted into
BAC (bacterial artificial chromosome) clone RP181F3 at the initiating
ATG codon of the first coding exon of the P2rx7 gene, so that EGFP
expression is driven by the regulatory sequences of the BAC gene.
Induction of status epilepticus was performed as previously described
(Engel et al., 2012b). Briefly, mice were anesthetized and placed in a
stereotaxic frame. Three partial craniectomies were performed to affix
cortical skull-mounted EEG electrodes (Bilaney Consultants), and EEG
was recorded using a Comet XL digital EEG (Grass Technologies). A
guide cannula was affixed for intra-amygdala targeting, and the skull
assembly was fixed in place with dental cement. Animals were removed
from the frame, allowed to recover, and then connected to the EEG. After
a baseline EEG, kainic acid (0.3 g in 0.2 l in PBS; Sigma-Aldrich) was
microinjected into the basolateral amygdala. The anticonvulsant loraz-
epam (6 mg/kg, i.p.; Wyeth) was administered 40 min later to curtail
morbidity and mortality (Engel et al., 2012b).
Mice were killed at different time points up to 21 d after status epilep-
ticus. All mice in this model develop recurrent spontaneous seizures
within 5 d (Mouri et al., 2008). At the time of their death, mice were
deeply anesthetized (pentobarbital) and perfused with saline to remove
intravascular blood components. Brains were then either flash frozen
whole in 2-methylbutane at30°C for histopathology or dissected on ice
to obtain whole or microdissected hippocampus. For immunofluores-
cencemicroscopy,micewere perfusedwith 4%paraformaldehyde (PFA)
after saline.
Brain and plasma levels of JNJ-47965567. JNJ-47965567 [N-((4-(4-
phenyl-piperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenyl-thio)
nicotinamide)]was providedby Janssen Research &Development. To con-
firm that JNJ-47965567 reaches the brain after systemic administration
and to assess how long brain levels remained detectable, adult mice were
injected with 30 mg/kg, i.p., JNJ-47965567, and killed at 15 and 30 min
and at 1, 2, 4, and 6 h (n  3 mice/time point). Blood samples were
centrifuged to isolate the plasma, and brains were frozen in dry ice,
followed by compound measurement by standard analytical methods
(Bhattacharya et al., 2013).We assumed that 1 g of brain tissue equals the
weight of a 1 ml volume of water.
Drug treatments. Animals were randomized after status epilepticus to
either the treatment or vehicle group. Specifically, animal identification
codes were chosen at random by one investigator, and then an indepen-
dent investigator assigned the animal to receive either vehicle or drug.
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Baseline seizure frequencies were unknown to investigators at the time of
assignment to treatment. Animals in the treatment group received twice-
daily injections of 30mg/kg, i.p., JNJ-47965567 for 5 d, beginning on day
11 after status epilepticus. Control animals received twice-daily injec-
tions of vehicle (30% -cyclodextrin sulfobutyl ethers and sodium salt
diluted in distilled water (Toronto Research Chemicals).
Epilepsy monitoring. Continuous EEG recordings in drug studies were
performed using implantable EEG telemetry devices (Data Systems In-
ternational; Mouri et al., 2008). Transmitters (model F20-EET, Data
Sciences International) were implanted in a subcutaneous pocket at the
time of the surgical procedures to equip mice for intra-amygdala kainic
acid injections, and were used to record bilateral EEG from skull. Three
weeks of EEG data were acquired for each animal, beginning from the
time of status epilepticus until the end of the study (day 21). One animal
that did not enter status epilepticus before the time of lorazepam admin-
istration was excluded from the study. Spontaneous seizures were scored
blinded to treatment and defined as high-frequency (5 Hz), high-
amplitude (more than two times baseline) polyspike discharges of10 s
duration that were present on both EEG channels. Seizure termination
was defined as a return of EEG amplitude and frequency to baseline
values with or without postictal amplitude suppression. The main pa-
rameters measured were daily seizure frequency and average seizure du-
ration (Mouri et al., 2008; Engel et al., 2013).
To evaluate clinical behavior, up to 10 seizures per mouse were se-
lected at random for each period (baseline, treatment, andwashout), and
a score was assigned. Typically, 10 seizures were analyzed per mouse in
the vehicle group for each period but only 6 seizures per mouse were
scored in the JNJ-47965567 group during the on-drug and washout pe-
riod due to the reduced seizure frequency. No scores could be assigned
for two mice during JNJ-47965567 treatment and one mouse after JNJ-
47965567 washout due to the absence of any seizures. A score was attrib-
uted based on whether seizures were partial or secondarily generalized
(Narkilahti et al., 2003). Briefly, partial seizures were given a score of 1
and defined as comprising one or more of the following: sudden behav-
ioral arrest, facial automatisms, or unilateral forelimb clonus. Second-
arily generalized seizures were given a score of 2, as defined by bilateral
forelimb clonus, forelimb clonus and rearing, and forelimb clonus with
rearing and falling.
Histopathology and immunohistochemistry. For immunohistochemis-
try analyses, free-floating sections were permeabilized and blocked in
goat serum followed by incubation with antibodies against GFP (1:500;
Invitrogen), Iba1 (1:500; Wako Chemicals), NeuN (1:500; Merck Milli-
pore Ireland B.V.), GFAP (1:500; Santa Cruz Biotechnology), or Synap-
tophysin (1:500; Sigma-Aldrich Ireland) overnight at 4°C. Sections were
washed and then incubated with goat polyclonal secondary antibodies
coupled to Alexa Fluor 488 or Alexa Fluor 568 (BioSciences). To confirm
specificity, additional sections were incubated without the primary anti-
body. Nuclei were labeled by staining with DAPI (4,6-diamidino-2-
phenylindole dihydrochloride; Vector Laboratories), and sections were
examined under an epifluorescence microscope. Counts of Iba1 and
GFAP cells in the drug treatment study were performed blind to treat-
ment. Two representative regions within a hippocampal subfield were
randomly selected, and cells were counted under 40 lensmagnification
and averaged for each animal. Representative images of the Iba1/GFAP
staining were taken using the same exposure time without knowledge of
the treatment group. Confocal images were acquired with a Leica TCR
6500 microscope equipped with four laser lines (405, 488, 561, and 653
nm) using a 63 immersion oil objective.
RNA extraction and real-time quantitative PCR. RNA extraction was
undertaken as previously described using TRIzol (QIAzol Lysis Reagent,
Qiagen; Engel et al., 2013). Briefly, 1g of total RNAwas used to generate
cDNA by reverse transcription using SuperScript II reverse transcriptase
enzyme (Invitrogen). Quantitative real-time PCRwas performed using a
LightCycler 2.0 (Roche Diagnostics) in combination with QuantiTect
SYBR Green PCR kit (Qiagen) as per the manufacturer protocol, and
with 1.25M custom-designed pair primers (Primer 3.0, Sigma-Aldrich)
for the selected target genes. Data were analyzed by LightCycler 2.0 soft-
ware, normalized to the expression of -actin and represented as relative
quantification values. Primers were designed using Primer3 software
(http://frodo.wi.mit.edu) and were verified by BLAST (http://blast.ncbi.
nlm.nih.gov/Blast.cgi). Primer sequences were as follows: -actin: for-
ward, 5-gggtgtgatggtgggaatgg-3; reverse, 3-ggttggccttagggttcagg-5;
P2rx2: forward 5-atgggattcgaattgacgtt-3; reverse, 3-gatggtgggaat-
gagactgaa-5; and P2rx7: forward, 5-ctggcaggtgtgttccata-3; reverse
3-ttggcaagatgtttctcgtg-5.
Western blot analysis. Western blotting was performed as previously
described (Engel et al., 2012b). Proteins were extracted from human or
mouse hippocampus, separated by SDS-PAGE, transferred to nitrocellu-
lose membranes, and then immunoblotted with the following primary
antibodies: P2X2R and P2X7R (APR-004, APR-003; 1:500; Alomone
Labs), Synaptophysin (1:200; Sigma-Aldrich), GAPDH (1:1000; Cell Sig-
naling Technology), and-actin and-tubulin (1:1000; Sigma-Aldrich).
The specificity of the P2X receptor antibodies was confirmed by preab-
sorbing with the P2X7R peptide antigen or a peptide antigen against the
P2X4R (Alomone Labs). Horseradish peroxidase-conjugated goat anti-
rabbit or anti-mouse antibodies (dilution, 1:5000; Millipore) were then
applied and used as secondary antibodies. Protein bands were visualized
using SuperSignal West Pico Chemiluminescent Substrate (Pierce). Gel
band image densities were captured using a Fujifilm LAS-4000 imaging
system and analyzed using Alpha-EaseFC 4.0 software.
Human brain tissue samples. This study was approved by the Ethics
(Medical Research) Committee of Beaumont Hospital, Dublin (05/18),
and written informed consent was obtained from all patients. Patients
(n 12) were referred for surgical resection of the temporal lobe for the
treatment of intractable TLE. After temporal lobe resection, the hip-
pocampus was divided, with one piece frozen in liquid nitrogen and
stored at 80°C. The remaining bloc was processed for routine
pathological analysis, and samples were assessed for the presence of hip-
pocampal sclerosis and other pathological changes. Control (autopsy)
hippocampi (n 12) were obtained from 12 individuals with no history
of neurological disease from theUniversity ofMarylandBrain andTissue
Bank (Baltimore, MD). Groups were balanced for sex (6 males/6 females
ratio for both groups) and age [control group: average age, 38 years (age
range, 24–50 years); TLE group: average age, 37 years (age range, 18–49
years)]. The average postmortem interval was 6.5 h. Full details of control
subject and patient pathology and clinical data can be found in Tables 1
and 2.
Synaptosome preparation. Synaptosomes were prepared as reported
with modifications (Díaz-Herna´ndez et al., 2001a). Three independent
samples, each comprising pools of two ipsilateral hippocampi, were pre-
pared from control and epileptic mice (14 d post-status epilepticus).
Tissue was homogenized with 300 l of sucrose-TES buffer [0.25 M su-
crose; 5 mM TES (2-{[1,3-dihydroxy-2-(hydroxymethyl)-2-propanyl]
amino}ethanesulfonic acid), pH 7.4] on ice using a glass-Teflon douncer
with seven strokes at 700 rpm. Volume was adjusted using sucrose-TES
buffer, and the homogenized sample was centrifuged at 2000  g for 3
min at 4°C. The supernatant was recovered and then spun again at
9500 g for 13min at 4°C. Then, the supernatant was discarded, and the
pellet containing the synaptosomes resuspended in 2 ml of sucrose-TES
buffer and subsequently placed in the top of a Percoll gradient (3%, 10%,
and 23%). Each sample was centrifuged at 25,000 g for 11 min at 4°C.
Table 1. Autopsy control details
Donor Sex Age (years) Tissue Cause of death PMI (h)
C1 F 35 Hippocampus Multiple injuries 2
C2 F 24 Hippocampus Head injuries 7
C3 F 42 Hippocampus HASCVD 4
C4 M 32 Hippocampus Morphine intoxication 7
C5 M 41 Hippocampus Mixed drug intoxication 6
C6 M 29 Hippocampus Acute pancreatitis 8
C7 M 40 Hippocampus Hemopericardium 9
C8 M 39 Hippocampus Hemopericardium 16
C9 M 50 Hippocampus Acute alcohol intoxication 19
C10 F 46 Hippocampus HASCVD 18
C11 F 37 Hippocampus Asthma 16
C12 F 42 Hippocampus Cardiac arrhythmia 12
F, Female; HASCVD, hypertensive arteriosclerotic cardiovascular disease; M, male; PMI, postmortem interval.
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The fraction left between the 10% and 23% layers (the synaptosomes)
was extracted and diluted in 15 ml of HEPES-buffered medium
(HBM)-no Ca2 buffer [140 mM NaCl, 5 mM KCl, 5 mM NaHCO3, 1.2
mM NaH2PO4 (nonhydrous), 1 mM MgCl2 * 6 H2O, 10 mM glucose, and
10mMHEPES]. The suspensionwas spun at 20,000 g for 11min at 4°C,
and the pellet was resuspended in HBM  Ca2 buffer. Last, 200 l of
synaptosomes was gently dropped onto coverslips pretreated with poly-
L-lysine and laminin (Life Technologies). The coverslips containing
700 synaptosomes were then placed in a calcium-sensitive fluorescent
indicator (FURA- 2AM, Invitrogen) for calciummicrofluorimetric anal-
ysis or fixed in 4% PFA for immunostaining.
Calcium microfluorimetric analysis. Free intracellular calcium con-
centrations ([Ca 2]i) were monitored using the calcium sensitive
fluorescent indicator FURA-2AM (5 M), as previously described
(Díaz-Herna´ndez et al., 2001b). Synaptosomes were incubated in
HBM solution containing FURA2-AM for 40 min at 37°C and subse-
quently placed in a superfusion chamber (Warner Instruments) at-
tached to an epifluorescence microscope (Leica Microsystems). The
Ca 2 indicator was excited through a 100 fluorine objective (TE-
200; Nikon) with 510 nm light via an optical quartz guide. Fluores-
cence signals were collected at 340–380 nm, and ratios were
determined at 1 s intervals. [Ca 2]i responses to the P2X7R agonist
BzATP (30 M, 30 s; Sigma-Aldrich) were recorded over 1 min, and 2
min after a pulse of high K (100 mM, 30 s) was applied as a positive
control. Basal fluorescence was determined before the first applica-
tion of BzATP. To assess the proportion of synaptosomes responding
to BzATP, we set at 100% the total number of synaptosomes respond-
ing to K, and then compared the percentage of those that responded
to BzATP. Fluorescence was imaged for each region of interest and
analyzed usingMetaFluor Fluorescence Ratio Imaging Software (Mo-
lecular Devices). Data are represented as the normalized fluorescence
ratio F340/F380, which increases when [Ca 2]i rises.
Synaptosome preparation for Western blotting. Mouse hippocampi
were dissected on ice, and the tissue was homogenized in 10 ml of
ice-cold homogenizing buffer (0.32 M sucrose, 1 mM EDTA, 1 mg/ml
bovine serum albumin, and 5 mM HEPES, pH 7.4) in a glass-Teflon
douncer with 10 strokes at 4°C. Next, samples were centrifuged for
10 min at 3000 g at 4°C, and the supernatant recovered (cytoplasm
and synaptosomes). Samples were again centrifuged for 12 min at
14,000  g at 4°C, and the supernatant was discarded. Pelleted syn-
aptosomes were resuspended in 550 l of Krebs–Ringer buffer (140
mM NaCl, 5 mM KCl, 5 mM glucose, 1 mM EDTA, and 10 mM HEPES,
pH 7.4). Then, 450 l of Percoll (45% v/v) was added, and the two
components were mixed by gently inverting the tube. After a 2 min
spin at 14,000 g at 4°C, enriched synaptosomes were recovered and
resuspended in 1 ml of Krebs–Ringer buffer. Samples were again spun
for 30 s at 14,000  g, and the supernatant was discarded. The pellet
containing the synaptosomes was resuspended in assay buffer
(HEPES–Krebs buffer) and stored at 20°C.
Electrophysiological recordings. Brains were extracted from P2rx7-
EGFPmice 14 d after status epilepticus and quickly sectioned through
the sagittal plane. Brain slices (300 m thickness) were then attached
to an agarose cube using cyanoacrylate glue and placed on the stage of
a vibratome cuvette (Integraslice 7550, Campden Instruments) filled
with a saline solution (125 mM NaCl, 2.5 mM KCl, 1 mM CaCl2, 1.25
mM NaH2PO4, 26 mM NaHCO3, and 12 mM glucose, pH 7.4, 300
mOsm) at 4°C. Brain slices were kept in saline solution continuously
bubbled with carbogen (95% O2/5% CO2) at room temperature (RT)
for a maximum of 6 h before being transferred to the recording cham-
ber. This was attached to the stage of an upright microscope
(BX51W1, Olympus) and connected to a gravity-driven perfusion
pump system, which delivered the above-mentioned saline solution
at a rate of 2 ml/min at RT. A 63 water-immersion objective and a
DL-604 OEM camera (Andor Technology) were used for the EGFP
cell visualization in the dentate gyrus (DG) and CA1 regions of the
hippocampus. Electrophysiological recordings were performed with
an EPC10/2 patch-clamp amplifier using PatchMaster software
(HEKA Electronic). Patch pipettes were fabricated from borosilicate
capillaries (Kimble Chase) with a Narishige PP830 puller to a final
resistance of 5–6 M	 when filled with the intracellular solution [140
mM, N-methyl-D-glucamine (NMDG), 5 mM EGTA, 3 mM MgCl2,
10 mM HEPES, pH 7.2, adjusted with HCl,290 mOsm]. Whole-cell
currents measured at a holding voltage (Vh) of70 mV were filtered
at 3 kHz and sampled at 10 kHz. Series resistance was compensated by
80% and monitored throughout the experiment together with the cell
membrane capacitance. Considering an average series resistance of 10
M	, a neuron membrane capacitance of 7.06
 0.9 pF (n 22 cells),
and the molecular weight of NMDG (195.21 kDa), we estimated in
10 min the time needed for NMDG to equilibrate between the
patch pipette and the cytoplasm of the recorded cell (Pusch and Ne-
her, 1988). Drug applications therefore began 10 min after obtaining
the whole-cell configuration. Likewise, experiments in which series
resistance changed by20% or in which holding current exceeded 20
pA were not analyzed. BzATP (100M) was applied onto the recorded
cell by means of separated glass pipettes (3–5 m tip diameter) con-
nected to a pneumatic drug ejection system (PDES-02DX, npi). At
variance, the P2X7R antagonist A438079 (10 M; Sigma-Aldrich) was
administered through the perfusate 2 min before and during BzATP
application.
Data analysis. Data are presented as the mean 
 SEM. Two-group
comparisons were analyzed using Student’s t test and Mann–Whitney
(M-W) test for nonparametric data. Multi-subfield comparisons of gene
expression data (mRNA, protein), electrophysiological data, and glial
histopathology were analyzed by ANOVA with post hoc Bonferroni test
(parametric) or Dunn’s test (nonparametric) to correct for repeated
measures (Prism version 6, GraphPad). Statistical analysis of the drug
treatment study was performed by calculating theMann–Whitney statis-
tic (also known as Harrell’s c) using Newson’s command somersd (New-
son, 2006a,b). Calculations were adjusted for clustering within animals
using the Stata robust variance estimates. Hypothesis tests compared the
observed value of the Mann–Whitney statistic to the null value (0.5).
Additional statistical analysis of the effect of JNJ-47965567 on spontane-
ous seizures was performed using Stata and are included in the Results
section. Significance was accepted at p 0.05.
Table 2. TLE patient clinical and pathological details
Patient Sex Age (years) Tissue Diagnosis and other pathology findings
E1 M 30 Hippocampus Hippocampal sclerosis, dysembryoplastic neuroepithelial tumor, probable microscopic involving temporal stem
E2 F 33 Hippocampus Hippocampectomy: mesial temporal sclerosis
E3 F 49 Hippocampus Hippocampal sclerosis
E4 F 40 Hippocampus Hippocampal sclerosis
E5 M 43 Hippocampus Hippocampus: gliosis
E6 M 46 Hippocampus Minimal hippo gliosis
E7 F 18 Hippocampus Hippocampus: mesial temporal sclerosis
E8 M 19 Hippocampus Temporal stem hemosiderin deposition; no evidence of neoplasia or of hippocampal sclerosis
E9 M 40 Hippocampus Hippocampus astrocytosis: no evidence of inflammation or neoplasia
E10 F 38 Hippocampus Mesial temporal sclerosis
E11 F 33 Hippocampus Hippocampus neuronal loss, dentate fascia, and gliosis
E12 F 54 Hippocampus Mesial temporal sclerosis
F, Female; M, male.
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Results
Cell-specific increase in P2X7R expression in the epileptic
mouse hippocampus
We first sought to define the cell types that express the P2X7R in
an animal model of acquired TLE. Although there is little argu-
ment that microglia express the P2X7R, it is controversial
whether the receptor is present on neurons or astrocytes (Ander-
son and Nedergaard, 2006; Sperla´gh and Illes, 2014). Resolving
this issue may help to explain the mechanisms by which the
P2X7R modulates neuroinflammation and hyperexcitability. To
avoid the limitations of P2X7R antibody-based immunohisto-
chemistry approaches (Sim et al., 2004; Anderson and Neder-
gaard, 2006), we used a reporter mouse in which transcription of
the P2X7R also drives EGFP to enable the precise identification of
cells transcribing the receptor (Engel et al., 2012a; Jimenez-
Pacheco et al., 2013). Epilepsywas induced in thesemice by intra-
amygdala microinjection of kainic acid (Mouri et al., 2008; Engel
et al., 2012b). This produces status epilepticus and subsequent
damage to the ipsilateral CA3 subfield, along with some limited
injury to the CA1 and DG/hilar region. All mice develop recur-
rent spontaneous seizures within 5 d (Mouri et al., 2008).
Confocal microscopic analysis of hippocampal sections iden-
tified scattered EGFP cells in control P2rx7-EGFP mice (Fig.
1A), consistent with previous reports (Engel et al., 2012a). These
were mainly in the DG cell layer as well as occasionally present in
the CA3 subfield. EGFP cells had a mainly neuronal appear-
ance, although microglia-like EGFP cells were also observed
(Fig. 1A). EGFP cells were not normally found in the CA1 sub-
field (Fig. 1A).
Analysis of sections from the ipsilateral hippocampus of
P2rx7-EGFP mice 2 weeks after status epilepticus, when animals
had active epilepsy, detected dramatically increased EGFP stain-
ing (Fig. 1B). Numbers of EGFP cells weremost increased in the
CA1 subfield, often continuously along the length of the pyrami-
dal cell layer (Fig. 1B). This pattern was not present in the CA1
subfield in the contralateral hippocampus of epileptic P2rx7-
EGFPmice (data not shown). Increased numbers of EGFP cells
were also found in the granule cell layer of the DG (Fig. 1B).
Figure1. Increased expression of P2X7R in experimental and human epilepsy.A, Photomicrograph showing EGFP immunofluorescence in the hippocampus of a control P2rx7-EGFPmouse. Scale
bar, 125m. Panels below show higher-power images of CA1 (i) and DG (ii) hippocampal subfields from the P2rx7-EGFP control animal. Scale bar, 50m. Note that the constitutive EGFP appears
mainly in cells of theDG.B, Photomicrograph showingEGFP immunofluorescence in thehippocampusof anepileptic P2rx7-EGFPmouse14dafter status epilepticus. Scalebar, 125m.Panels below
show higher-power images of CA1 (i) and DG (ii) hippocampal subfields from the P2rx7-EGFP epileptic animal. Scale bar, 50m. C, Double-stained confocal immunofluorescence images showing
EGFP (green, GFP) and neuronalmarker NeuN (red), in the CA1 and DG subfields from epileptic P2rx7-EGFPmice. Scale bar, 50m.D, Immunofluorescence staining showing EGFP (green, GFP) and
microgliamarker Iba1 (red) in the CA3 subfield of a P2rx7-EGFP epileptic mouse. Scale bar, 20m. Images are representative of data from n 5 animals per group. E, Graph showing P2rx7mRNA
levels in the CA1, CA3, andDG subfields of control (Con) andepileptic (Epi)mice (n9/group; ANOVAwithBonferroni test, *p0.05).F, RepresentativeWesternblots (n1/lane) showingP2X7R
protein (70 kDa) within the CA1 and DG subfields in vehicle-injected control and epileptic mice.-Tubulin is shown as a guide to loading. G, RepresentativeWestern blot (n 1/lane) showing
P2X7Rprotein in thehippocampusofhumancontrol andTLEpatients. GAPDH is shownasaguide to loading.H, Graph showingP2X7Rprotein levels inCA1andDGsubfields in vehicle-injected control
and epileptic animals (n 9/group; ANOVA with Bonferroni test, *p 0.05). I, Graph showing P2X7R protein levels in the hippocampus of TLE patients when compared with controls (n
12/group; Student’s t test, *p 0.05). J, Antibody preabsorption test. Western blots show a P2X7R band (left panels) in epileptic mouse and human hippocampal samples (n 1/lane) and
elimination of the band (middle panels) when the antibody was preincubated with the antigen peptide for the P2X7R (pep7r). Right panels show the band remains when antibodies were
preincubated with the peptide antigen for P2X4R (pep4r).
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Within the CA3 lesion site, where neuron loss was extensive,
there were only occasional EGFP cells (data not shown).
Counterstaining hippocampal sections from epileptic P2rx7-
EGFP reporter mice with antibodies against NeuN determined
that themajority of EGFP cells in both theCA1 subfield andDG
were neurons (Fig. 1C). In the ipsilateral CA3 lesion area, there
were only a few NeuN cells remaining in epileptic mice, and
these were typically EGFP (data not shown).
EGFP cells were also found in each hippocampal subfield,
including CA3, that stained for Iba1, indicating that a population
of cells expressing the P2rx7 were microglia (Fig. 1D; data not
shown). We did not detect any EGFP cells that labeled for the
astrocyte marker GFAP (data not shown).
P2X7R upregulation in experimental and human epilepsy
To extend the reporter mouse data, we performed real-time
quantitative PCR analysis of P2rx7 transcript levels in the hip-
pocampus of wild-type C57BL/6 epileptic mice. P2rx7 mRNA
levels were increased in the ipsilateral hippocampus from mice
14 d after status epilepticus (Fig. 1E). As a control, we assessed
levels of P2rx2, another member of the P2X receptor family re-
ported to be regulated in the short term after status epilepticus
(Engel et al., 2012b). P2rx2 mRNA levels were unchanged in all
three ipsilateral hippocampal subfields (data not shown).
Wenext assessed protein levels of the receptor byWestern blot
analysis. A band corresponding to the predicted weight of P2X7R
was detected at 70 kDa in control samples (Fig. 1F). P2X7R
protein levels were increased within the CA1 subfield of epileptic
mice (Fig. 1F,H) but were similar to controls in the DG and CA3
subfields (Fig. 1F,H; data not shown). There were no differences
in P2X2R protein levels between control and epilepsy samples in
any subfield (data not shown).
To explore the clinical relevance of these findings, we analyzed
P2X7R protein levels in a set of surgically resected hippocampi
from TLE patients and compared them with those of autopsy
control subjects (Tables 1, 2). Western blot analysis determined
that P2X7R protein levels were higher in TLE patient samples
comparedwith those of control subjects (Fig. 1G,I). P2X2R levels
in TLE patients were similar to those in control subjects (data not
shown). A simulated autopsy delay using mouse brain deter-
mined that the higher P2X7R levels in TLE samples were not due
to an effect of postmortem interval (data not shown). As a con-
firmation of antibody specificity and since a double band was
observed in samples, perhaps a result of splice variants or post-
translational modifications (Sperla´gh and Illes, 2014), we per-
formed preabsorption tests. The P2X7R protein band was
eliminated when epileptic mouse or human samples were preab-
sorbed with the control peptide antigen for P2X7R, but not an-
other P2X peptide antigen (Fig. 1J). Together, these results
confirm that P2X7R upregulation is a feature of the pathophysi-
ology of the hippocampus in experimental and human epilepsy.
Increased P2X7R functional responses in experimental
epilepsy
It is unknown whether P2X7R-gated functional responses are
altered in epileptic tissue. We hypothesized that the increased
P2X7R expression in epilepsy would be associated with increased
cellular responses to activation of the receptor. To test this idea,
we performed patch-clamp recordings of agonist-evoked inward
currents in hippocampal slices. For these experiments, we again
used epileptic P2rx7-EGFP mice to enable us to distinguish
P2rx7-expressing cells from adjacent cells not transcribing the
receptor. The neuronal subtype of the recorded cells (granule
neurons, interneurons, or otherwise) was not determined.
Application of the P2X7R agonist BzATP produced minimal
responses in recordings fromEGFP cells in theDG (Fig. 2A–C).
In contrast, the application of BzATP to DG cells expressing
EGFP resulted in a rapid inward current into cells from the same
animal (Fig. 2A–C). There was a significant main effect of group
(F(1,23)  10.5; p  0.05); post hoc analysis showed that BzATP-
evoked currents were significantly larger in the EGFP cells dur-
ing the first and the second pulse than in the non- EGFP cells.
Similar results were obtained in patch-clamp recordings from
cells in the CA1 subfield (Fig. 2A–C). There was a significant
main effect of group (F(1,26) 36.52; p 0.005); post hoc analysis
showed that BzATP-evoked currents were significantly larger in
the EGFP cells during the first, second, and third pulse than in
the non-EGFP cells.
To confirm that this was specific to the P2X7R, experiments
were repeated in the presence of a bath-applied P2X7R antagonist
(Fig. 2D). Agonist-evoked currents in EGFP cells in both the
DG and the CA1 subfield were blocked by the P2X7R antagonist
A-438079 (Fig. 2D). These data confirm that functional P2X7R-
gated responses are present in hippocampal cells from epileptic
mice expressing the receptor.
The P2X7Rhas been reported to localize to presynaptic sites in
the hippocampus where it may contribute to neurotransmitter
release (Armstrong et al., 2002; Sperla´gh et al., 2002). To deter-
mine whether this localization was changed in epilepsy, we pre-
pared synaptosomes from control and epilepticmice, and stained
them with specific P2X7R antibodies. Preabsorption of the anti-
bodies with the antigen peptide eliminated staining (data not
shown). In synaptosomes from control mice, there wasmoderate
overlap of P2X7R immunoreactivity with the synaptic marker
synaptophysin (Fig. 2E). In sections from epileptic mice, this
colocalization was more prominent, consistent with increased
synaptic P2X7R localization (Fig. 2E). These findings were sup-
ported byWestern blot analysis of P2X7R levels in synaptosomes,
in which higher levels of P2X7R protein were found in epileptic
compared with nonepileptic mice (Fig. 2F).
Last, we sought to determine whether the increased synaptic
P2X7Rhad functional effects on responses to agonist application.
Synaptosomes were prepared from control or epileptic mice, and
agonist-evoked intracellular calcium changes were recorded (Fig.
2G,H). Overall, a greater proportion of synaptosomes responded
to BzATP application with a calcium response in epileptic mice
compared with control mice (Fig. 2G). In synaptosomes from
control mice, BzATP application resulted in a rapid and short-
lasting increase in [Ca2]i (Fig. 2H). In synaptosomes from epi-
lepticmice, BzATP application produced a similar initial calcium
response, but was also frequently accompanied by additional in-
tracellular calcium spikes that continued after agonist application
(Fig. 2H, I). Together, these findings suggest that there is in-
creased synaptically localized P2X7R in epilepsy and that func-
tional responses may be enhanced or aberrant.
Treatment of mice with a P2X7R antagonist produces lasting
suppression of epileptic seizures
To test whether targeting the P2X7Rhas an effect on spontaneous
seizures, we sought a P2X7R antagonist that is centrally available
after systemic injection to treat epileptic mice. In previous work,
we performed intracerebral injections of A-438079 to study the
effect of P2X7R inhibition on status epilepticus (Engel et al.,
2012b; Jimenez-Pacheco et al., 2013). However, recent work in
rodents revealed that A-438079 has poor CNS penetration fol-
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Figure 2. Increased functional responses of P2X7R to agonist stimulation in epilepsy. A, B, Increased current responses of EGFP cells when compared with non-EGFP cells from the same
animal in DG and CA1 hippocampal subfields to the P2X7R agonist BzATP (100M) during patch-clamp recordings in hippocampal slices fromP2rx7-EGFP epilepticmice [n 10 (EGFP, DG), n
4 (EGFP, CA1), n 4 (non-EGFP, DG), and n 5 (non-EGFP CA1). Data in A and summary data in B, ANOVA with Bonferroni test, *p 0.05, **p 0.01, ***p 0.001 compared with
non-EGFP group. C, Representative traces showing increased inwardly directed nonsensitizing currents evoked by BzATP (100M) fromEGFP cells (green lines)when comparedwith non-EGFP
cells (black lines) in epileptic EGFP-P2rx7mice. Horizontal lines represent the time of BzATP application.D, Graph showing significantly suppressed responses to 100M BzATP in EGFP cells in the
presence of the specific P2X7R antagonist A438079 (10M) in brain slices fromepileptic P2rx7-EGFPmice (n 3/group). ANOVAwith Bonferroni test, **p 0.01, ***p 0.001. E, Graph showing
the percentage of P2X7R synaptosomes in hippocampal samples from control (Con) and epileptic (Epi) mice (n  3/group). F, Representative Western blot (Figure legend continues.)
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lowing systemic administration and is rapidly eliminated from
the brain (Bhattacharya et al., 2013; Mesuret et al., 2014). We
therefore selected JNJ-47965567, a recently described potent and
specific antagonist of the P2X7R that is centrally available after
systemic injection in rodents (Bhattacharya et al., 2013).
We first confirmed that JNJ-47965567 reaches the brain after
systemic injection in naive (nonepileptic) mice (Fig. 3A). Intra-
peritoneal injection of mice with JNJ-47965567 (30 mg/kg) re-
sulted in a rapid increase, with high levels of the drug in both
plasma and brain (Fig. 3A). High plasma and brain levels of JNJ-
47965567 were also detected in mice killed 2 h after injection. In
mice killed 4–6 h after injection, levels had fallen back toward
baseline levels (Fig. 3A; data not shown). Thus, systemic injec-
tions of JNJ-47965567 are well suited for achieving the necessary
sustained brain levels for the planned studies.
Figure 3B shows the experimental design used to assess the
effects of JNJ-47965567 and the distribution of spontaneous sei-
zures over time for the two groups.Micewere equippedwith EEG
telemetry units and were subjected to status epilepticus induced
by intra-amygdala kainic acid. Video-EEG monitoring com-
menced immediately, and the freely moving mice were recorded
continuously for the next 3 weeks. Ten days after status epilepti-
cus, all mice were epileptic and displayed frequent spontaneous
seizures, as previously reported (Mouri et al., 2008). Mice were
then assigned in a random, blinded manner to receive either
vehicle or JNJ-47965567, starting on day 11. While undergoing
treatment, mice received twice-daily injections of drug or vehicle
for 5 d. Treatment was then discontinued, and mice were re-
corded for the next 6 d. This additional recording time enabled us
to assess seizure frequency after washout of the drug and to ad-
dress any potential disease-modifying effect of JNJ-47965567.
Before commencing drug treatment, both groups of mice
were experiencing frequent spontaneous seizures, which is con-
sistent with previous reports in this model (Fig. 3B,C). There
were no differences in spontaneous seizure frequency between
groups before treatment (M-W statistic is 0.49, p  0.844, cor-
rected for clustering of observations with animals; Fig. 3C).
During treatment, spontaneous seizure rates declined in mice
injected with JNJ-47965567 compared with mice injected with
vehicle, and this reached statistical significance (p 0.043; M-W
statistic 0.36,meaning that therewas a 64%probability of there
being fewer seizures in an animal injected with JNJ-47965567
than in an animal injected with vehicle during the drug phase;
Fig. 3C).
During the washout period, spontaneous seizure rates in
vehicle-treated mice continued at a similar rate of approximately
six per day. In contrast, spontaneous seizure rates in mice previ-
ously given JNJ-47965567 remained lower (approximately 2 per
day), and this was significant comparedwith vehicle-treatedmice
(M-W statistic 0.31, p 0.002; Fig. 3C). Thus, there was a 69%
probability of there being fewer seizures in an animal injected
with JNJ-47965567 than in an animal injectedwith vehicle during
the washout phase.
The duration of spontaneous seizures was compared between
vehicle and JNJ-47965567 using a Mann–Whitney statistic ad-
justed for clustered observations within animals. There were no
differences between groups in the duration of seizures at baseline
(p  0.212), during treatment (p  0.287), or during washout
(p  0.419; Fig. 3D). Representative examples of spontaneous
seizures captured using EEG telemetry are shown in Figure 3E.
We also undertook additional statistical analysis because of
the excess of zeros (no seizures) in the data, using zero-inflated
Poisson regressionwith robust variance estimation to account for
the clustering of data within animals. We further examined the
excess of zero seizure counts in the treatment phase. This data-
driven approach models the data as deriving from the following
two populations: a population of animals experiencing seizures
in varying numbers, including animals that will experience no
seizures during a particular observation period; and a population
of animals that are protected from seizures, who will also have
zero observed seizures. Thus, observations of zero seizures are a
mixture of the two populations. During the on-treatment phase,
the zero-inflated Poisson model showed that the JNJ-47965567
group showed a higher incidence of zero seizures than the control
group [incidence rate ratio (IRR), 2.5; p 0.001]. Although the
incidence of seizures, adjusted for this excess of zero scores, was
lower in the JNJ-47965567 group (IRR, 0.70), the effect was not
significant (p  0.398). During the washout phase, by contrast,
there was no evidence of an excess of zero scores in the JNJ-
47965567-treated animals (IRR, 1.6; p 0.184), but there was a
lower incidence of seizures in the treated group (IRR, 0.39; p 
0.008).
Clinical seizures during and after treatment with
JNJ-47965567
The behavioral (clinical) features of spontaneous seizures in the
animals featured a mixture of partial (focal; score of 1) and sec-
ondarily generalized (score of 2) seizures. A selection of up to 10
video-captured seizures was analyzed per mouse during each
monitoring period (baseline, on-drug andwashout; seeMaterials
and Methods; Fig. 3F). To analyze these data, we used multino-
mial logistic regression, with SEs adjusted for the clustering of
observations within animals. Using a seizure score of 1 (partial)
as the reference category, animals in the JNJ-47965567-treated
groupdid not differ from those in the vehicle-treated group in the
baseline phase in either the probability of having severe seizures
(secondarily generalized) or having no seizures. They had an in-
creased probability of having no seizures both in the treatment
phase (p 0.001) and in the washout phase (p 0.001). How-
ever, they did not differ from vehicle in the probability of having
severe seizures in either the treatment or washout phases. That is,
JNJ-47965567 treatment is preventing seizures from occurring
rather than altering seizure severity.
JNJ-47965567 treatment reduces microgliosis and astrogliosis
in epileptic mice
Finally, we examined tissue sections from vehicle- and JNJ-
47965567-treatedmice obtained at the end of recordings (i.e., 6 d
after drug treatment ceased).Microgliosiswas detected by immu-
nostaining for Iba1, whereas astrocytes were detected by staining
for GFAP. As expected, there was widespread microgliosis in tis-
sue sections from epileptic mice given vehicle (Fig. 4A–D). Mi-
4
(Figure legend continued.) and graph showing increased P2X7R protein levels in isolated
synaptosomes from epilepticmicewhen comparedwith controlmice. Synaptophysinwas used
as a loading control (n 2 hippocampi/lane, 5 lanes/group).G, Graph showing the percentage
of isolated synaptosomes displaying positive responses to BzATP (30 M) administration in
control and epileptic synaptosomes [n 7 (control) and n 8 (epilepsy) coverslips of synap-
tosomes, generated fromthreepools ofn2hippocampi].H, Representative traces of [Ca 2]I
increments elicited by 30M BzATP and 100mM K in control (Con) and epileptic (Epi) synap-
tosome preparations (individual synaptosomes analyzed; Con 708, Epi 990). I, Graph
showing the percentage of synaptosomes displaying “multi-responses” after BzATP adminis-
tration in control and epileptic synaptosomes preparations. Data in E–G and I, Student’s t test,
*p 0.05. ***p 0.005 compared with indicated group.
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crogliosis was most prominent in areas of pathology, such as the
CA3 subfield, but was also apparent in the CA1 and DG (Fig.
4A–D). In contrast, microgliosis was significantly lower in mice
treated with JNJ-47965567 (Fig. 4A–D). Quantification revealed
that this reduction was significant in all hippocampal subfields
(Fig. 4E). The reduction represented an apparent reduction in the
number as well as the immunoreactivity of the Iba1 microglia
(Fig. 4E).
Last, we assessed astrogliosis in tissue sections stained for
GFAP. The hippocampus from epileptic mice given vehicle dis-
played dramatic astrogliosis (Fig. 4F–I). This was prominent in
all subfields examined, including CA1, CA3, and the DG (Fig.
4F–I). Astrogliosis was lower in all subfields in JNJ-47965567-
treated mice (Fig. 4F–J). The reduction represented an apparent
reduction in the number as well as the immunoreactivity of the
GFAP astrocytes (Fig. 4J).
Figure 3. JNJ-47965567 treatment reduces spontaneous seizures inmice. A, Plasma and brain concentrations of JNJ-47965567 at various time points after intraperitoneal injection of 30mg/kg
into naive mice (n 3 per time point). B, Experimental design for testing effects of JNJ-47965567 and plots of spontaneous seizures for mice in each group over time. Mice underwent status
epilepticus and were then injected twice daily with JNJ-47965567 (30 mg/kg) during days 11–15. Drug/vehicle was discontinued from day 16 until day 21. Mice were then killed. C, Box plots
depicting the average number of seizures per day in vehicle-injected and drug-treated epileptic mice during the baseline days 5–10 before treatment, days 11–15 during JNJ-47965567 (JNJ) or
vehicle (Veh) treatment, and days 16–21 duringwashout (n 9/group;Mann–Whitney statistic adjusted for the clustering of datawithin animals, *p 0.05; **p 0.01). Individual data points
plotted beside the boxes are the averaged data for individual mice during each phase of the experiment. D, Box plots depicting the average duration of epileptic seizures for each treatment period
(n 9/group; Mann–Whitney statistic adjusted for clustering of data within animals). There were no differences between groups at any phase of the study. Individual data points plotted beside
the boxes are the averaged data for individual mice during each phase of the experiment. E, Representative examples of spontaneous seizures detected using EEG telemetry at baseline, during
treatment and during washout for vehicle-treated and JNJ-47965567-treated mice. Red traces represent the EEG from the contralateral hemisphere, black traces are the EEG from ipsilateral
hemisphere.F, Clinical scores are depicted as a spine plot. Thegraphicwas basedon10 seizure ratings/animal for eachphase of the study (Base, baseline; Treat, treatment;Wash,washout) andwere
scored as 1 (partial seizure), score 2 secondarily generalized, or no seizure available for a rating. The figure illustrates the comparable severity of seizureswhen they occurred butwith fewer seizures
occurring in JNJ-47965567-treated animals.
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Discussion
Current AEDs fail to control seizures in30% of patients and do
not have an impact on the underlying pathophysiology (Bialer
and White, 2010; Pitka¨nen and Lukasiuk, 2011; Kobow et al.,
2012). Thus, there is an unmet need for the novel targetable
pathomechanisms that underlie TLE. Altered purinergic signal-
ing has been suggested as a pathomechanism in epilepsy (Burn-
stock, 2008; Sperla´gh and Illes, 2014), and ATP is released after
CNS injury at levels sufficient to activate the P2X7R (Wang et al.,
2004). P2X7R activation probably serves an important role in the
early, protective phase of neuroinflammation by triggering mi-
croglia activation and inflammasome-mediated IL-1 release,
among other effects (Roth et al., 2014; Sperla´gh and Illes, 2014).
However, chronic or aberrant P2X7R expression may sustain
neuroinflammation, induce neuronal death, and promote hyper-
excitability (Murphy et al., 2012; Sperla´gh and Illes, 2014;
Franceschini et al., 2015). Previous work had found P2X7R over-
expression in epilepsy, but the cell types and function of the re-
ceptor remained uncertain, and targeting had only been explored
inmodels of acute status epilepticus (Vianna et al., 2002; Rappold
et al., 2006; Dona´ et al., 2009; Kim and Kang, 2011; Engel et al.,
2012b; Jimenez-Pacheco et al., 2013). Here we used a reporter
mouse to gain insight into the cell phenotypes transcribing the
P2rx7 in epilepsy. We found pronounced neuronal transcription
in the CA1 and DG subfields, which are less damaged in this
model. This is generally consistent with the cellular distribution
that emerges in the wake of acute status epilepticus in the same
model (Engel et al., 2012b). Other studies may have missed this
population due to reliance on immunohistochemical ap-
proaches, which lack sensitivity and specificity (Miras-Portugal
et al., 2003; Sim et al., 2004; Anderson and Nedergaard, 2006).
We also found microglia transcribing P2rx7 within the CA3 sub-
field, which is the main site of neuron loss and the source of
spontaneous seizures in the model (Li et al., 2008). This is
consistent with earlier reports using immunohistochemical ap-
proaches in a rat model of TLE (Rappold et al., 2006). Transcrip-
Figure 4. Decreased astrogliosis and microgliosis in JNJ-47965567-treated epileptic mice. A–D, Photomicrographs of representative Iba1 staining of the hippocampus from vehicle- (Veh) and
JNJ-47965567 (JNJ)-treated epilepticmice showing field views (A) and20 lensmagnifications (B–D) of individual subfields from the sameanimal. Note, thedecrease in thenumber of Iba1 cells
and the immunoreactivity in mice treated with the specific P2X7R inhibitor JNJ-47965567. E, Graph showing the quantification of Iba1microglia found in each hippocampal subfield of vehicle-
and JNJ-47965567-treated mice killed 6 d after drug washout at the end of recordings (n 9/group; ANOVA with Bonferroni test, **p 0.01, ***p 0.001). F–I, Photomicrographs of
representative GFAP staining in the hippocampus from vehicle- and JNJ-47965567-treated epileptic mice, showing field views (F) and 20 lens magnifications (G–I) of individual subfields from
the same animal. J, Quantification of GFAP cells found in each hippocampal subfield from vehicle- and JNJ-47965567-treated mice killed 6 d after drug washout at the end of recordings (n
9/group; ANOVA with Bonferroni test, *p 0.05. **p 0.01). Scale bars: A, F, 200m; B, G, 100m.
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tion of P2rx7 did not appear to occur in astrocytes, which is
consistent with other reports (Duan et al., 2003; Jabs et al., 2008;
Hirayama et al., 2015). Together, these data suggest that P2rx7
transcriptional responses occur in specific cell populations in a
pathology-dependent manner in this model. Functional P2X7R
responses were evident from soma recordings from cells with the
appearance of neurons in the CA1 and DG, and we also detected
P2X7R responses in synaptosomes, which is consistent with the
presynaptic localization reported by others (Armstrong et al.,
2002; Vianna et al., 2002; Yu et al., 2008; Engel et al., 2012b).
Neuronal P2X7Rs have been reported to influence the release of
GABA and glutamate (Armstrong et al., 2002; Sperla´gh et al.,
2002), andour findings suggest direct neuromodulatory effects of
P2X7R that offer a potential explanation for why targeting this
receptor alters seizures. That is, blocking neuronal P2X7R may
modulate neurotransmitter release and prevent synchronous
network firing.
Amajor finding in the present study was that the treatment of
epileptic mice with a P2X7R antagonist reduced the number and
duration of spontaneous seizures. The animal model we used
features spontaneous seizures at a frequency of approximately six
per day with attendant clinical (tonic, clonic) features (Mouri et
al., 2008; Jimenez-Mateos et al., 2010; Liu et al., 2013). This has
advantages relative to othermodels for testing AEDswhere spon-
taneous seizures may showmarked clustering or are mainly sub-
clinical (Williams et al., 2009; Maroso et al., 2011; Klein et al.,
2015). Here we used JNJ-477965567, a recently described cen-
trally available P2X7R antagonist that achieves98% brain pro-
tein occupancywith anEC50 of3 nM (Bhattacharya et al., 2013).
Twice-daily injections of JNJ-47965567 reduced spontaneous
seizure rates in this model by50% during treatment, although
seizure suppression was even more evident after treatment
had ceased. This may reflect the time required for the P2X7R
inhibitor to result in beneficial effects on the underlying patho-
physiology such as gliosis to take effect. This degree of seizure
suppression is similar to the effects of conventional AEDs in
kainate-induced epilepsy in rodents, including valproate, carba-
mazepine, topiramate, and levetiracetam (Grabenstatter et al.,
2007; Klein et al., 2015). The effect is also comparable to the
performance of VX-765, an IL-1 synthesis inhibitor, in the in-
trahippocampal kainate model in mice (Maroso et al., 2011).
Since seizures in focal kainate models of acquired epilepsy are
typically refractory to conventional AEDs (Riban et al., 2002;
Klein et al., 2015), these data suggest that P2X7R targetingmay be
suitable as an adjunctive treatment for TLE patients with phar-
macoresistant seizures. Indeed, data here and in previous studies
of the neocortex (Jimenez-Pacheco et al., 2013) show that the
P2X7R is upregulated in human TLE.
Disease-modifying effects are increasingly recognized as a
necessary property of any future AED (Bialer and White, 2010;
Kobow et al., 2012). An important and unexpected finding in the
present study was that spontaneous seizure rates did not increase
once treatment with JNJ-477965567 ended, but remained65%
lower (approximately two seizures per day) than in vehicle-
treated epileptic mice. This cannot be due to the drug remaining
in the brain based on the pharmacokinetic data reported here and
in previous studies (Bhattacharya et al., 2013). The most likely
explanation, therefore, is that JNJ-47965567 had a disease-
modifying effect in themodel. Thismarkedly contrasts the results
with conventional AEDs in post-status epilepticus models where
spontaneous seizure rates, if altered at all, promptly return to
baseline on cessation of treatment (Chakir et al., 2006; Graben-
statter et al., 2007; Klein et al., 2015). What is the mechanism of
the sustained seizure-suppressive effect of JNJ-477965567? The
best understood effect of P2X7R activation is the release of IL-1
from activated microglia. IL-1 is directly proexcitatory via ef-
fects on NMDA receptor and driving astrogliosis (Viviani et al.,
2003; Allan et al., 2005). However, in studies with VX-765, a
direct inhibitor of IL-1 biosynthesis, the number of spontane-
ous seizures returned to baseline within 24 h of treatment inmice
with kainate-induced epilepsy (Maroso et al., 2011). Thus, the
blockade of IL-1 is not a sufficient explanation of the results
with JNJ-47965567. A key observation here was that the hip-
pocampus of mice previously treated with JNJ-47965567 dis-
played marked reductions in both microgliosis and astrogliosis.
This not only reduced immunoreactivity but appeared to reduce
the numbers of both cell types. This may account for the disease-
modifying effects. Notably, VX-765 does not reduce astrogliosis
ormicrogliosis in epilepticmice (Maroso et al., 2011), and reduc-
tions in gliosis are not usually seen after the treatment of rodents
with commonAEDs (Chakir et al., 2006). The effect onmicroglia
may be due to the drug directly blocking a pathway known to be
required for microglia activation (Monif et al., 2009). However,
the contribution of microgliosis to spontaneous seizures remains
uncertain (Devinsky et al., 2013). The lasting antiseizure effects
may also derive from reduced astrogliosis. Indeed, recent studies
(Ortinski et al., 2010; Robel et al., 2015) demonstrate that astro-
gliosis alone, in the absence of other pathology, is sufficient to
cause epilepsy in mice. There are several mechanisms by which
astrogliosis may promote spontaneous seizures, including de-
pleting endogenous adenosine levels and altering the reuptake of
neurotransmitters (Devinsky et al., 2013). Astrocyte-derived
ATP may further promote seizures by promoting the release of
IL-1 from microglia (Bianco et al., 2005). An additional mech-
anism underlying the observed effects of JNJ-47965567 may be
direct effects on neurotransmitter release (Sperla´gh et al., 2002).
A number of limitations should be considered. Despite ran-
domizing animals to the treatment or control group, there was a
trend toward less frequent and shorter duration spontaneous sei-
zures during the baseline period in the JNJ-47965567 group,
which could predispose this group to being more responsive to
treatment. The measurement of brain levels of the mice treated
with JNJ-47965567 was performed in healthy mice, but analysis
during and after treatment in epileptic mice would provide more
valuable insight into the relationship to seizure suppression. Ad-
justments to the dose, frequency, or duration of treatment with
JNJ-47965567 could yield improvements in short-term or long-
term seizure suppression. Further experiments will be needed to
determine whether the glial changes are a direct or indirect result
of blocking P2X7R signaling. We found some disconnect be-
tween the transcriptional data from the reporter mouse and
mRNA/protein analysis. This may be due to a nonlinear relation-
ship between EGFP expression and P2rx7 levels, the stability of
the channel or reporter protein, a consequence of the microdis-
section technique, or circuit reorganization in the epileptic hip-
pocampus with loss of neuronal protein balanced by increased
glial levels. Another explanation is that post-transcriptional si-
lencing of the P2rx7 in this model, for example by microRNA
(Zhou et al., 2008; Jimenez-Mateos et al., 2015), affected the re-
lationship between transcription and protein levels. Last, while
ATP release sufficient to activate the P2X7R has been demon-
strated after spinal cord injury (Wang et al., 2004), we lack in vivo
spatiotemporal data onATP release during spontaneous seizures.
In summary, the present study shows that targeting the P2X7R in
experimental epilepsy results in a reduction in spontaneous sei-
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zures and accompanying gliosis. This receptor may represent a
novel target for the treatment of refractory TLE.
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